Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Subject Collections
    • JASN Podcasts
    • Archives
    • Saved Searches
    • ASN Meeting Abstracts
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Subscriptions
  • More
    • About JASN
    • Alerts
    • Advertising
    • Editorial Fellowship Program
    • Feedback
    • Reprints
    • Impact Factor
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
Open Access

COVID-19–Associated Acute Kidney Injury: Learning from the First Wave

Ron Wald and Sean M. Bagshaw
JASN January 2021, 32 (1) 4-6; DOI: https://doi.org/10.1681/ASN.2020101401
Ron Wald
1Division of Nephrology, St. Michael’s Hospital and the University of Toronto, Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean M. Bagshaw
2Department of Critical Care Medicine, University of Alberta, Edmonton, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • acute kidney injury
  • COVID-19

As the coronavirus disease 2019 (COVID-19) pandemic swept through American hospitals in the early part of 2020, the multisystem nature of the disease quickly became apparent, with AKI featuring as a prominent complication of severe acute respiratory syndrome coronavirus 2 infection.1 Severe infection likely drives an immunologic storm, leading to tubular, vascular, and in some cases, glomerular injury. A direct viral cytopathic effect on the kidney is a subject of debate.2,3

In this issue of JASN, two investigative groups provide a comprehensive description of their experience with COVID-19–associated AKI.4,5 Chan et al.4 report on the epidemiology of COVID-19–associated AKI among nearly 4000 patients admitted at a five-hospital health system in New York City. As part of the Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 project that recruited patients from 67 United States hospitals, Gupta et al.5 followed 3099 critically ill patients with COVID-19 and focused on those who received RRT in the context of AKI.

Collectively, these timely studies deliver three crucial messages: (1) AKI afflicted nearly half of all patients hospitalized with COVID-19 and the majority of those admitted to the intensive care unit (ICU), (2) 20% of critically ill patients with COVID-19 received RRT, and (3) survivors of COVID-19–associated AKI often have incomplete recovery of kidney function at hospital discharge, with one-third of patients who received acute RRT having a persistent requirement for dialysis at the time of hospital discharge.

The high frequency of AKI among patients hospitalized with COVID-19 in United States hospitals contrasts with reports from China, where AKI tended to be less frequent.6,7 It is unclear if this relates to differences in ascertainment, thresholds for hospitalization, ICU care (e.g., concomitant use of mechanical ventilation and fluid management), or the prevalence of AKI risk factors. The proportion of critically ill patients initiating RRT was especially high, which is consistent with reports from patients with COVID-19 in the United Kingdom8 but higher than what was observed in patients with influenza A subtype H1N1.9,10 The receipt of RRT correlates with both severity of AKI and overall illness acuity, but the ultimate decision to commence RRT is complex and guided by a variety of clinical and logistic factors as well as clinician judgement. Neither of the two papers described the specific triggers for RRT. Recent trials have shown that the preemptive initiation of RRT, specifically before a metabolic or fluid-related emergency of AKI supervenes, does not confer improved survival but may portend a higher risk of persistent dialysis dependence and iatrogenic complications.11

With the procurement of ventilators dominating pandemic preparedness efforts in early 2020, dialysis capacity emerged as a “blind spot” as patients with COVID-19–associated AKI overwhelmed health care systems in New York City and other regions.12 Well-established acute RRT programs struggled due to a lack of machines, supplies, and personnel. Scarcity prompted centers to rapidly alter their usual RRT strategies; novel approaches included “sharing” continuous RRT (CRRT) machines between two patients, each receiving a daily 10- to 12-hour session, and the utilization of peritoneal dialysis,13 which is not traditionally used in North American ICUs for the treatment of AKI. The unexpected deluge of patients with AKI forced rapid adaptation and creative problem-solving. Kidney programs preparing for future COVID-19 surges must proactively prepare for scenarios in which their RRT resources may again become stressed, necessitating the development of well-conceived backup plans. It is also hoped that future surges will see enhanced coordination between health systems and manufacturers to ensure an adequate supply of dialysis hardware and disposables across modalities, with flexible plans to rapidly shift supplies and staff to sites facing the greatest needs.

The dialysis prescription in COVID-19–associated AKI presents unique considerations. Irrespective of RRT modality, the optimal ultrafiltration target for patients with COVID-19 is uncertain. Hypoxemic respiratory failure and acute respiratory distress syndrome, central features of severe COVID-19, may be exacerbated by fluid accumulation, which is worsened by AKI. Whether and how fast to remove fluid with ultrafiltration are uncertain. On one hand, more rapid fluid removal may improve oxygenation and accelerate liberation from mechanical ventilation. However, ultrafiltration may predispose patients to hypotension and secondary organ injury.

COVID-19 is associated with a syndrome of hypercoagulability with implications for RRT-related anticoagulation.14 Clinicians should consider using anticoagulation for all therapies unless an unequivocal contraindication exists. For CRRT in particular, our experience and that of others have highlighted the challenges in maintaining circuit patency with standard anticoagulation regimens.15 A combination of systemic heparin and regional citrate anticoagulation may be an effective way of maximizing circuit patency, although more information on the safety and efficacy of this approach is needed. Peritoneal dialysis may represent a viable alternative for patients with recalcitrant clotting on CRRT or conventional hemodialysis.

Although the long-term outcomes of COVID-19–associated AKI have yet to be described, the studies by Chan et al.4 and Gupta et al.5 remind us that AKI survivors often have incomplete recovery of kidney function at discharge and may benefit from follow-up after their acute hospitalization. Virtual care and telemedicine, which have rapidly gained traction during the pandemic, may prove to be especially valuable in the care of this vulnerable population. Follow-up should include serial assessments of kidney function and albuminuria, attention to BP and cardiovascular risk factors, and a thorough review of medications. The latter would include tailoring drugs and doses to the patients’ evolving kidney function as well as the reintroduction of key drugs that may have been appropriately stopped during the hospitalization. Patients still receiving dialysis at hospital discharge require close surveillance for kidney recovery and when appropriate, the thoughtful weaning of dialysis.

The papers in this issue of JASN have provided us with a vivid understanding of the effect of COVID-19–associated AKI in hospitalized patients while highlighting issues that are relevant to the wider population of patients with AKI. Future research will hopefully provide insights on AKI prevention and mitigation strategies in patients with COVID-19, inform optimal RRT prescriptions for this population, and describe the long-term prognosis of AKI survivors. Most importantly, clinicians and hospital administrators must internalize the lessons of spring 2020 to ensure that health systems will have adequate resources and capacity to deliver safe and effective RRT during the next wave of illness.

Disclosures

S. Bagshaw and R. Wald have received unrestricted research funding and speaker fess from Baxter, and research support from Canadian Institutes of Health Research, outside the submitted work. R. Wald reports consultancy agreements with DURECT; ownership interest in CVS; research funding from Baxter; honoraria from Otsuka; scientific advisor or membership as Editorial Board member of CJASN and Kidney Medicine at Kidney360; and other interests/relationships as a contributor to UpToDate.

Funding

None.

Acknowledgments

The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendations. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or JASN. Responsibility for the information and views expressed herein lies entirely with the author(s).

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related articles, “AKI in Hospitalized Patients with COVID-19,” and “AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19,” on pages 151–160 and 161–176, respectively.

  • Copyright © 2021 by the American Society of Nephrology

References

  1. ↵
    1. Berlin DA,
    2. Gulick RM,
    3. Martinez FJ
    : Severe COVID-19 [published online ahead of print May 15, 2020]. N Engl J Med 10.1056/NEJMcp2009575pmid:32412710
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kudose S,
    2. Batal I,
    3. Santoriello D,
    4. Xu K,
    5. Barasch J,
    6. Peleg Y, et al
    .: Kidney biopsy findings in patients with COVID-19. J Am Soc Nephrol 31: 1959–1968, 2020pmid:32680910
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Sharma P,
    2. Uppal NN,
    3. Wanchoo R,
    4. Shah HH,
    5. Yang Y,
    6. Parikh R, et al
    .; Northwell Nephrology COVID-19 Research Consortium: COVID-19-associated kidney injury: A case series of kidney biopsy findings. J Am Soc Nephrol 31: 1948–1958, 2020pmid:32660970
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Chan L,
    2. Chaudhary K,
    3. Saha A,
    4. Chauhan K,
    5. Vaid A,
    6. Zhao S, et al
    .: AKI in hospitalized patients with COVID-19. J Am Soc Nephrol 32: 151–160, 2021
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Gupta S,
    2. Coca SG,
    3. Chan L,
    4. Melamed ML,
    5. Brenner SK,
    6. Hayek SS, et al
    .: AKI treated with renal replacement therapy in critically ill patients with COVID-19. J Am Soc Nephrol 32: 161–176, 2021
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Xie J,
    2. Wu W,
    3. Li S,
    4. Hu Y,
    5. Hu M,
    6. Li J, et al
    .: Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: A retrospective multicenter study. Intensive Care Med 46: 1863–1872, 2020pmid:32816098
    OpenUrlPubMed
  7. ↵
    1. Brienza N,
    2. Puntillo F,
    3. Romagnoli S,
    4. Tritapepe L
    : Acute kidney injury in coronavirus disease 2019 infected patients: A meta-analytic study [published online ahead of print July 2, 2020]. Blood Purif 10.1159/000509274pmid:32615555
    OpenUrlPubMed
  8. ↵
    Intensive Care National Audit and Research Centre: ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland. London, Intensive Care National Audit and Research Centre, 2020
  9. ↵
    1. Martin-Loeches I,
    2. Papiol E,
    3. Rodríguez A,
    4. Diaz E,
    5. Zaragoza R,
    6. Granada RM, et al
    .; H1N1 SEMICYUC Working Group: Acute kidney injury in critical ill patients affected by influenza A (H1N1) virus infection. Crit Care 15: R66, 2011pmid:21342489
    OpenUrlPubMed
  10. ↵
    1. Bagshaw SM,
    2. Sood MM,
    3. Long J,
    4. Fowler RA,
    5. Adhikari NK
    ; Canadian Critical Care Trials Group H1N1 Collaborative: Acute kidney injury among critically ill patients with pandemic H1N1 influenza A in Canada: Cohort study. BMC Nephrol 14: 123, 2013pmid:23763900
    OpenUrlCrossRefPubMed
  11. ↵
    1. Bagshaw SM,
    2. Wald R,
    3. Adhikari NKJ,
    4. Bellomo R,
    5. da Costa BR,
    6. Dreyfuss D, et al
    .; STARRT-AKI Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group; United Kingdom Critical Care Research Group; Canadian Nephrology Trials Network; Irish Critical Care Trials Group: Timing of initiation of renal-replacement therapy in acute kidney injury [published correction appears in N Engl J Med 383: 502, 2020 10.1056/NEJMx200016]. N Engl J Med 383: 240–251, 2020pmid:32668114
    OpenUrlPubMed
  12. ↵
    1. Goldfarb DS,
    2. Benstein JA,
    3. Zhdanova O,
    4. Hammer E,
    5. Block CA,
    6. Caplin NJ, et al
    .: Impending shortages of kidney replacement therapy for COVID-19 patients. Clin J Am Soc Nephrol 15: 880–882, 2020pmid:32345750
    OpenUrlFREE Full Text
  13. ↵
    1. El Shamy O,
    2. Patel N,
    3. Abdelbaset MH,
    4. Chenet L,
    5. Tokita J,
    6. Lookstein R, et al
    .: Acute start peritoneal dialysis during the COVID-19 pandemic: Outcomes and experiences. J Am Soc Nephrol 31: 1680–1682, 2020pmid:32546597
    OpenUrlFREE Full Text
  14. ↵
    1. Abou-Ismail MY,
    2. Diamond A,
    3. Kapoor S,
    4. Arafah Y,
    5. Nayak L
    : The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res 194: 101–115, 2020pmid:32788101
    OpenUrlPubMed
  15. ↵
    1. Shankaranarayanan D,
    2. Muthukumar T,
    3. Barbar T,
    4. Bhasin A,
    5. Gerardine S,
    6. Lamba P, et al
    .: Anticoagulation strategies and filter life in COVID-19 patients receiving continuous renal replacement therapy: A single-center experience [published online ahead of print September 17, 2020]. Clin J Am Soc Nephrol 10.2215/CJN.08430520pmid:32943397
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 32 (1)
Journal of the American Society of Nephrology
Vol. 32, Issue 1
January 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
COVID-19–Associated Acute Kidney Injury: Learning from the First Wave
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
COVID-19–Associated Acute Kidney Injury: Learning from the First Wave
Ron Wald, Sean M. Bagshaw
JASN Jan 2021, 32 (1) 4-6; DOI: 10.1681/ASN.2020101401

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
COVID-19–Associated Acute Kidney Injury: Learning from the First Wave
Ron Wald, Sean M. Bagshaw
JASN Jan 2021, 32 (1) 4-6; DOI: 10.1681/ASN.2020101401
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • COVID-19 and APOL1: Understanding Disease Mechanisms through Clinical Observation
  • The Aftermath of AKI: Recurrent AKI, Acute Kidney Disease, and CKD Progression
  • Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases
Show more Up Front Matters

Editorials

  • COVID-19 and APOL1: Understanding Disease Mechanisms through Clinical Observation
  • The Aftermath of AKI: Recurrent AKI, Acute Kidney Disease, and CKD Progression
  • Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • AKI in Hospitalized Patients with COVID-19
  • AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19
  • PubMed
  • Google Scholar

Keywords

  • acute kidney injury
  • COVID-19

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire